Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ

NCT07408856 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT07408856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07408856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ
Lead sponsor
Providence Health & Services
Phase
Phase 1
Overall status
Recruiting
Start date
September 16, 2026
Completion date
May 31, 2035
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ductal carcinoma in situ, lobular carcinoma in situ